mylotarg
pfizer europe ma eeig - gemtuzumab ozogamicin - leukämie, myeloisch, akut - antineoplastische mittel - mylotarg ist indiziert für die kombinationstherapie mit daunorubicin (dnr) und cytarabine (arac) für die behandlung von patienten im alter 15 jahre und mehr mit zuvor unbehandeltem, de-novo-cd33-positiven akuten myeloischen leukämie (aml), außer akute promyelocytic leukämie (apl).
blincyto
amgen europe b.v. - blinatumomab - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
kyprolis
amgen europe b.v. - carfilzomib - multiples myelom - antineoplastische mittel - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukämie, lymphozytär, chronisch, b-zell - antineoplastische mittel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
zurampic
grünenthal gmbh - lesinurad - hyperurikämie - antigout-präparate - zurampic, ist in kombination mit einem xanthin-oxidase-hemmer, bei erwachsenen für die unterstützende behandlung von hyperuricaemia bei gicht-patienten (mit oder ohne tophi) angegeben, die nicht ziel serum-harnsäure-spiegel mit einer angemessenen dosis von ein xanthin-oxidase erreicht haben inhibitor allein.
alphabux 120 mg filmtabletten
so.se. pharm s.r.l. (8179487) - febuxostat - filmtablette - teil 1 - filmtablette; febuxostat (32477) 120 milligramm
febuxostat beta 120 mg filmtabletten
betapharm arzneimittel gmbh (3364323) - febuxostat 0.5 h<2>o - filmtablette - teil 1 - filmtablette; febuxostat 0.5 h<2>o (43376) 123,42 milligramm
febuxostat zentiva 120 mg filmtabletten
zentiva pharma gmbh (8075753) - febuxostat - filmtablette - teil 1 - filmtablette; febuxostat (32477) 120 milligramm
febuxostat abz 120 mg filmtabletten
abz-pharma gmbh - geschäftsanschrift - (4238075) - febuxostat 0.5 h<2>o - filmtablette - teil 1 - filmtablette; febuxostat 0.5 h<2>o (43376) 123,42 milligramm
febuxostat-ratiopharm 120 mg filmtabletten
ratiopharm gmbh (3087881) - febuxostat 0.5 h<2>o - filmtablette - teil 1 - filmtablette; febuxostat 0.5 h<2>o (43376) 123,42 milligramm